pharmaceutical-investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical-investing AbbVie Announces Topline Results for Epcoritamab from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
pharmaceutical-investing AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
pharmaceutical-investing AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
pharmaceutical-investing AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
pharmaceutical-investing West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
pharmaceutical-investing MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
pharmaceutical-investing AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
pharmaceutical-investing SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
pharmaceutical-investing AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
pharmaceutical-investing AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
pharmaceutical-investing LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
BlackRock® Canada Announces Final January Cash Distributions for the iShares® Premium Money Market ETF
